Substance / Medication

Conivaptan

Overview

Active Ingredient
conivaptan
RxNorm CUI
302285

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Goldsmith Steven R, Gilbertson David T, Mackedanz Shari A et al. · J Card Fail · 2011
PMID: 22123359RCT
Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Koren Michael J, Hamad Abdullah, Klasen Sally et al. · Am J Health Syst Pharm · 2011
PMID: 21515866RCT
Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian Caroline, Lesch Christine, Berger Karen · Pharmacotherapy · 2017
PMID: 28295447Observational
Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
Kalra Sanjay, Efrati Shai, Arthur John M et al. · Am J Health Syst Pharm · 2011
PMID: 21411800Observational
Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.
Naidech Andrew M, Paparello James, Liebling Storm M et al. · Neurocrit Care · 2010
PMID: 20568023Observational
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
Goldsmith Steven R, Elkayam Uri, Haught W Herbert et al. · J Card Fail · 2008
PMID: 18926434Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Conivaptan (substance)
SNOMED CT
421858002
UMLS CUI
C0966107
RxNorm CUI
302285

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.